Congratulations to our talented team on their larger roles in developing cures for heart disease!

CTX-promotions-2023-01-25-1.1-o

Congratulations to our diligent and talented team members who are taking on larger roles as we develop our novel technologies to cure atherosclerosis!

  • Dr. Daniel Clemens: Vice President of Biology
  • Dr. Keivan Sadrerafi: Director of Chemistry
  • Dr. Prerna Bhargava: Senior Scientist
  • Darren Dinh: Senior Research Associate/ Lab Manager

It is through the hard work of our dedicated team that we are able to take on the world’s leading killer!

About Cyclarity

Cyclarity Therapeutics, Inc., is pursuing a mission to treat the underlying causes of age-related disease. The company develops simple and direct interventions targeting oxidized cholesterol using rationally designed molecules, to provide the first true disease-modifying treatments for common age-related conditions such as atherosclerosis, heart attack and stroke. Its products are based on novel derivatives of a well-known, safe compound and a new way of looking at cardiovascular disease. For more information, please visit www.cyclaritytx.com or send an email to press@cyclaritytx.com

Contact:

Mike Kope
CEO of Corporate Affairs
Cyclarity Therapeutics, Inc.
press@cyclaritytx.com

Cyclarity News:

Cyclarity Therapeutics Announces Clinical Advisory Board

Cyclarity Therapeutics, Inc. today announced its newly formed Clinical Advisory Board to guide its clinical development of drug candidate UDP-003 for the treatment and prevention of atherosclerosis, primary coronary artery disease, and associated cardiovascular diseases.

Read More »